April 1st 2021
The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.
September 12th 2012
August 29th 2012
Charges dropped against sales exec over LHRH kickbacks
July 8th 2004A federal judge in Boston has acquitted a former sales executive at TAP Pharmaceutical Products Inc. who was charged with conspiring to pay kickbacks and bribes in exchange for prescriptions of leuprolide acetate (Lupron), the Chicago Tribune reported.
Therapeutic options for sexual dysfunction still growing
July 1st 2004Do you think the three available phosphodiesterase type-5 inhibitors-vardenafil hydrochloride (Levitra), tadalafil (Cialis), and sildenafil citrate (Viagra)-are essentially the same, or do they have distinct advantages in the treatment of ED?
Antibiotic, alpha-blocker ineffective for CP/CPPS
July 1st 2004San Francisco--A commonly prescribed antibiotic and alpha-blocker appear to be ineffective in the treatment of men with moderate to severe chronic prostatitis/chronic pelvic pain syndrome of long duration. Results of a multicenter study found that both ciprofloxacin and tamsulosin-used primarily in the treatment of urinary tract infections and BPH, respectively-offered no significant benefit in the treatment of chronic prostatitis in patients who were heavily pretreated and had long-standing symptoms.
Testosterone patch improves sex drive in surgically menopausal women
June 24th 2004An investigational female testosterone patch (Intrinsa) significantly increases satisfying sexual activity and sexual desire in surgically menopausal women with hypoactive sexual desire disorder (HSDD), according to preliminary findings of a large-scale phase III safety and efficacy study.
Chemo studies mark new era in prostate Ca care
June 1st 2004Studies of the effect of chemotherapy in men with metastatic prostatecancer have been enticing and, at the same time, disappointing. While showingPSA response in some cases, these studies have previously failed to demonstrateimproved survival. This is all about to change, and for the better. We areentering an exciting new era in the management of this patient population.
Neoadjuvant chemo shows mixed results in PCa
June 1st 2004San Francisco--Continuing a trend of mixed results seen in previousstudies, neoadjuvant chemotherapy with docetaxel (Taxotere) resulted ina significant PSA response but failed to induce any histologic changes inlocally advanced prostate cancer, Cleveland Clinic investigators reportedat the AUA annual meeting.
Former TAP employee sentenced in LHRH case
May 27th 2004A former regional account manager for TAP Pharmaceutical Products, Inc., has been convicted for making false declarations to a U.S. Grand Jury. The conviction of Joanne Richardson is related to her role in illegal marketing practices concerning TAP's LHRH agonist leuprolide acetate (Lupron).
AUA: Post-marketing studies of ED therapies are under review
May 27th 2004The latest update of AUA guidelines for management of organic erectile dysfunction will focus on novel treatment recommendations and suggestions for study designs that minimize conflicts of interest in post-marketing comparisons of oral drug therapies.
Study results fuel interest in use of alpha-blockers for stone management
May 25th 2004Results from an ex vivo study demonstrating effects of the nonselective alpha-1 receptor antagonist doxazosin (Cardura) on ureteral contractility raises questions about the role of alpha-blocker treatment in the management of ureteral stone disease, say urologists from the University of Wisconsin.
Various therapies manage kidney stone disease
May 12th 2004Mission Pharmacal provides the following therapies for the medical managementof kidney stone disease: potassium citrate wax matrix (Urocit-K) tablets;tiopronin (Thiola) tablets; acetohydroxamic acid (Lithostat) tablets; andcellulose sodium phosphate powder (Calcibind).
Formulation decreases risk of recurrent stone formation
May 12th 2004Orthophosphate formula (Uro-KP-Neutral) from Star Pharmaceuticals decreasesthe risk of recurrent calcium oxalate stone formation and the growth ofresidual stones following lithotripsy. In addition, the formulation is agood source of supplemental potassium, sodium, and phosphorus, accordingto the company.